How much muscle do you lose on a GLP-1, and can you get it back?
Key takeaways
Dr. Linda's take
This is one of the questions I most want people to ask before they start, not after. The fear underneath it is usually some version of "am I going to end up smaller but weaker, and did I do this to myself?"
Here is the honest shape of the answer. Yes, a portion of the weight you lose is lean mass. No, that is not a special curse of these medications, and it happens with essentially every method of losing a meaningful amount of weight. And no, losing some lean mass on a scan does not automatically mean losing the muscle that lets you climb stairs and stay steady on your feet. Whether it comes back, and in what form, depends a great deal on what you do while you are on the medication and after. That part is yours to control.
How much of the weight you lose on a GLP-1 is actually muscle?
Start with the size of the change, because it sets the context. In the STEP 1 trial, adults with obesity lost a mean of 14.9% of their body weight on once-weekly semaglutide over 68 weeks, about 15.3 kg, compared with 2.4% on placebo. When you lose that much weight, your body does not lose pure fat. Some lean mass goes with it.
How much? A 2026 meta-analysis of 20 randomized trials, covering 15,782 participants, found that lean mass made up 25% to 39% of the total weight lost on incretin medications: 35.2% with semaglutide, 25.4% with tirzepatide, and 26.8% with liraglutide. A separate pooled analysis put lean mass loss at roughly 25% of the total weight lost on GLP-1 receptor agonists.
So the fraction is real, and it is not tiny. That is the number worth knowing before you start.
Is that lean mass loss unique to GLP-1 medications?
No, and this is the part that reframes the whole worry. In that same 2026 meta-analysis, lifestyle interventions produced comparable proportional lean mass loss at 26.2%, and the authors concluded the proportion of weight lost as lean mass is broadly comparable between incretin medications and lifestyle change.
The cleanest illustration comes from a head-to-head with placebo. In the tirzepatide SURMOUNT-1 body-composition substudy, of the weight participants lost about 75% was fat and 25% was lean mass, and that split was essentially the same for tirzepatide and for placebo. Read that twice. The people losing weight without the drug lost lean mass in the same proportion as the people on it, which tells you it is a feature of losing weight, not something the medication adds on top.
This matters because it moves the question from "is this medication damaging my muscle" to "how do I lose weight, by any method, while protecting the muscle I want to keep."
Why does losing lean mass on a scan not always mean losing strength?
Because lean mass is a mixed bag. It is not a synonym for muscle. It includes body water, organ tissue, and connective tissue, so when a scan shows lean mass dropping, some of that is fluid and other tissue shifting with a smaller body, not just muscle disappearing.
There is a useful signal in the data on this. In the pooled analysis, even though absolute lean mass fell, the relative lean mass, meaning lean mass as a percentage of total body weight, was unaffected. In plain terms, you became a smaller person who was still made up of roughly the same share of lean tissue. That is not nothing, and it is why the clinical significance of the lean mass number is genuinely debated among researchers rather than settled. The honest position is that some lean mass loss is expected, and whether it meaningfully weakens you depends on how much of it is muscle and what you do to defend it.
Does the muscle come back if you stop the medication or regain weight?
Two things tend to happen when people stop, and it helps to separate them.
First, the weight usually returns. One year after semaglutide was withdrawn in the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost, ending with a net loss of 5.6% from where they started. In the tirzepatide SURMOUNT-4 trial, people switched to placebo regained substantially, gaining 14.0% over the year while those who stayed on treatment lost a further 5.5%. Weight regain after stopping is common, and the medications work by being taken, not by being finished.
Second, and more reassuring for your specific worry: the body composition that comes back is not stacked against you the way people fear. A systematic review of weight cycling found that none of the eighteen studies examining lean body mass reported a decrease in it across repeated cycles of loss and regain, and the majority found no adverse effects on body composition overall. A separate weight-loss-and-regain study found that regained fat returned roughly in proportion to the weight regained, while muscle came back in its own pattern rather than lagging permanently behind. So the lean mass you lose is not gone for good. It moves with your weight, and it responds to what you ask of it.
Can you protect the muscle in the first place, or build it back?
Yes, and this is where your effort actually changes the outcome. Two levers have the strongest evidence.
Resistance training is the first. Supervised resistance exercise lasting more than 10 weeks can produce large gains in lean mass, on the order of 3 kg, and about a 25% increase in strength in men and women, which is why the authors of a Diabetes Care review proposed that tailored resistance training be recommended as an adjunct to incretin therapy. We go deeper on this in does strength training protect muscle better than protein alone.
Protein is the second. Across 49 studies, protein supplementation increased fat-free mass gains during resistance training by about 0.30 kg, with no further benefit once total intake passed roughly 1.62 g per kilogram per day. And during weight loss specifically, a higher-protein diet mitigated the loss of fat-free mass by about 0.43 kg compared with a standard-protein diet. Adding structured exercise to weight loss helped too, preserving nearly half of the fat-free mass that would otherwise have been lost. If you want the specific numbers to aim for, how much protein do you need to protect muscle walks through the target.
The takeaway is not "muscle loss is inevitable." It is "muscle loss is expected, partly reversible, and strongly shaped by two things you can start today." If you are trying to figure out whether any of this fits your situation, our eligibility quiz is a place to begin.
The honest bottom line
A quarter to a third of the weight you lose on these medications tends to be lean mass. That sounds alarming until you learn two things: the same happens when people lose weight without the medication, and a good share of that lean mass is water and other tissue rather than pure muscle. When people stop, weight and body composition largely return, and repeated cycles have not been shown to leave you with less muscle over time.
What decides how strong you feel is not the medication by itself. It is whether you eat enough protein and keep asking your muscles to work while your body gets smaller. That part was always yours.
Frequently asked questions
How much of GLP-1 weight loss is muscle versus fat?
A 2026 meta-analysis of 20 randomized trials, covering 15,782 participants, found that lean mass made up 25% to 39% of the total weight lost on incretin medications: 35.2% with semaglutide, 25.4% with tirzepatide, and 26.8% with liraglutide. The rest was fat, and lean mass is not the same as muscle, since it also includes water and organ tissue.
Is the muscle loss worse on a GLP-1 than with dieting?
No. In that same 2026 meta-analysis, lifestyle interventions produced comparable proportional lean mass loss at 26.2%, and the authors concluded the proportion of weight lost as lean mass is broadly comparable between incretin medications and lifestyle change. In the tirzepatide SURMOUNT-1 body-composition substudy, of the weight participants lost about 75% was fat and 25% was lean mass, and that split was essentially the same for tirzepatide and for placebo. The lean mass loss travels with weight loss itself, not with the medication.
Does muscle come back after you stop a GLP-1?
Weight tends to return after stopping. One year after semaglutide was withdrawn in the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost, ending with a net loss of 5.6% from where they started. A review of weight cycling found no study reported a decrease in lean body mass across repeated loss-and-regain cycles, which is reassuring that lean mass is not permanently stripped away.
Will I regain fat but not muscle after stopping?
That is the common fear, but the evidence does not support it as an inevitability. In a weight-loss-and-regain study, regained fat returned roughly in proportion to the weight regained, and muscle returned in its own pattern rather than being permanently left behind. What you do with resistance training strongly shapes how much muscle you keep and rebuild.
How do I keep as much muscle as possible on a GLP-1?
The two best-supported levers are resistance training, which can add lean mass and strength, and adequate protein, which reduces fat-free mass loss during weight loss. Combining exercise with weight loss preserved nearly half of the fat-free mass that would otherwise have been lost.
References
1. The New England journal of medicine (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-18).
2. Diabetes, obesity & metabolism (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PubMed PMID 41877354. https://pubmed.ncbi.nlm.nih.gov/41877354/ (Accessed 2026-07-18).
3. Metabolism: clinical and experimental (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. PubMed PMID 39719170. https://pubmed.ncbi.nlm.nih.gov/39719170/ (Accessed 2026-07-18).
4. Diabetes, obesity & metabolism (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. PubMed PMID 39996356. https://pubmed.ncbi.nlm.nih.gov/39996356/ (Accessed 2026-07-18).
5. Diabetes, obesity & metabolism (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. PubMed PMID 35441470. https://pubmed.ncbi.nlm.nih.gov/35441470/ (Accessed 2026-07-18).
6. JAMA (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. PubMed PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/ (Accessed 2026-07-18).
7. Current obesity reports (2024). The Physiological Effects of Weight-Cycling: A Review of Current Evidence. PubMed PMID 38172475. https://pubmed.ncbi.nlm.nih.gov/38172475/ (Accessed 2026-07-18).
8. International journal of obesity (2005) (2013). Effect of weight loss and regain on adipose tissue distribution, composition of lean mass and resting energy expenditure in young overweight and obese adults. PubMed PMID 23381557. https://pubmed.ncbi.nlm.nih.gov/23381557/ (Accessed 2026-07-18).
9. Diabetes care (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. PubMed PMID 38687506. https://pubmed.ncbi.nlm.nih.gov/38687506/ (Accessed 2026-07-18).
10. British journal of sports medicine (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. PubMed PMID 28698222. https://pubmed.ncbi.nlm.nih.gov/28698222/ (Accessed 2026-07-18).
11. The American journal of clinical nutrition (2012). Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. PubMed PMID 23097268. https://pubmed.ncbi.nlm.nih.gov/23097268/ (Accessed 2026-07-18).
12. Diabetes, obesity & metabolism (2026). Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat-Free and Skeletal Muscle Mass in Overweight or Obese Individuals-A Systematic Review With Pairwise Meta-Analysis and Network Meta-Analysis of Randomized Controlled Studies. PubMed PMID 42144246. https://pubmed.ncbi.nlm.nih.gov/42144246/ (Accessed 2026-07-18).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-18.*
Keep reading
How much weight can you lose on retatrutide?
Retatrutide is investigational, but its phase 2 trial is striking Ā· the highest 12-mg dose cut body weight a mean 24.2% at 48 weeks. Dr. Linda lays out the real numbers, the context against approved options, and why phase 2 results can still shift.
Can you take a GLP-1 if you have hypothyroidism?
Treated hypothyroidism is not a reason to rule out a GLP-1, and the boxed warning is about a rare thyroid cancer, not an underactive gland Ā· but because these medicines slow gastric emptying, levothyroxine absorption is worth monitoring with a clinician.
Can a GLP-1 lower heart disease risk after menopause?
The SELECT trial found semaglutide lowered major cardiovascular events by 20% in people with established heart disease and obesity without diabetes Ā· but it was not a menopause trial, so Dr. Linda explains where the evidence is solid and where it is extrapolated.
Were Black and Latina women included in GLP-1 weight-loss trials?
Black and Latina women were enrolled in the major semaglutide and tirzepatide weight-loss trials, and subgroup analyses found the medicines worked across race and ethnicity Ā· but non-white participants were under-represented relative to disease burden.
Does a GLP-1 lower testosterone in women with PCOS?
GLP-1 medicines are linked to a modest, mostly indirect drop in testosterone and free androgen index in women with PCOS, with the biggest shifts when paired with metformin. Dr. Linda explains the evidence and the honest limits.
Does Florida heat affect how you store your GLP-1?
Florida heat is real, and your GLP-1 pen has rules. Dr. Linda Moleon, MD lays out the exact refrigerator range, room-temperature limits, and discard windows straight from the Wegovy and Zepbound FDA labels, so your medication still works when you need it.